GlaxoSmithKline Plc plans to produce 1 billion doses of a vaccine adjuvant — a booster that can help any brand of shot — to support immunization against the Covid-19 pandemic next year.
The adjuvant can reduce the amount of vaccine required per dose, allowing more people to be immunized, and create longer-lasting immunity, Glaxo said in a statement Thursday. The U.K. drugmaker in April agreed to provide its technology to help develop an experimental vaccine with French pharma giant Sanofi.
Glaxo is among dozens of companies in the hunt for a vaccine, seen as the key to halting the pandemic and reopening economies around the world. The global death toll has climbed past 350,000.
The London-based company said it plans to make the adjuvant at sites in Europe, Canada and the U.S. It has started manufacturing after reviewing its supply network and finding it could increase capacity.
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.